(17S,21R)-8,21-bis(dimethylamino)-11-hydroxy-5-(2-methylpropyl)-13,18-dioxo-16-oxa-5-azahexacyclo[12.9.0.03,12.04,9.015,17.017,22]tricosa-3,9,11,14,19-pentaene-19-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: (17S,21R)-8,21-bis(dimethylamino)-11-hydroxy-5-(2-methylpropyl)-13,18-dioxo-16-oxa-5-azahexacyclo[12.9.0.03,12.04,9.015,17.017,22]tricosa-3,9,11,14,19-pentaene-19-carboxamide
• 化学式: C₃₀H₃₈N₄O₅
• 分子量: 534.6
• InChiKey: ITVBIRFQOKBBHK-ZCWPEXRSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE TÉTRACYCLINES
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2014036502A2

  公开（公告）日：2014-03-06

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.